POSC110 Cost-Effectiveness of Durvalumab Following Chemoradiotherapy in Unresectable Stage III NSCLC Patients in the US: An Update Based on 5-Year Pacific Data

Saved in:
Bibliographic Details
Published in:Value in health 2022-01, Vol.25 (1), p.S108-S108
Main Authors: Mooradian, MJ, Taylor, S, Ramsden, R, van Keep, M, Dunlop, W, Brannman, L, Yong, C
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2021.11.515